<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03889457</url>
  </required_header>
  <id_info>
    <org_study_id>35RC18_3002_AntiCoagChoice</org_study_id>
    <nct_id>NCT03889457</nct_id>
  </id_info>
  <brief_title>What Treatment for Patients With Phlebitis or Pulmonary Embolism ?</brief_title>
  <acronym>AntiCoagChoice</acronym>
  <official_title>Patients' Choice in Terms of Anticoagulant Therapy in Venous Thrombo- Embolism Disease. AntiCoagChoice Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SFMV (French Society of Vascular Medicine)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the &quot;anticoagchoice&quot; study is to analyze the preferences of people suffering
      from phlebitis, in terms of anticoagulant, to improve adherence to these treatments, to adapt
      the medical prescriptions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Venous thromboembolism (VTE) is the third leading cause of cardiovascular death, with an
      increase in annual incidence with age. With the advent of direct oral anticoagulants, the
      management of deep vein thrombosis and pulmonary embolism has evolved in recent years and
      these treatments are widely prescribed. There are studies comparing the different
      anticoagulant treatments used in venous thrombosis, which show no inferiority of treatment
      (injectable or oral) compared to others. Drug delivery modalities have been shown to affect
      adherence, and thus treatment efficacy. It seems fundamental to focus on patients' drug
      preferences in VTE to ensure the best possible compliance. These preferences seem to depend
      on the personal history of each patient. In addition, no studies have been conducted on
      patient preferences for anticoagulant therapy for VTE: this is the goal of the
      &quot;anticoagchoice&quot; study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2019</start_date>
  <completion_date type="Anticipated">February 12, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 12, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to analyze patient treatment preferences in venous thromboembolic disease.</measure>
    <time_frame>the time required for a consultation: 30 minutes</time_frame>
    <description>The primary outcome: To compare the proportion of patients choosing oral anticoagulation vs patients choosing injectable route.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>compare patients choosing oral anticoagulation vs patients choosing an injectable route</measure>
    <time_frame>the time required for a consultation: 30 minutes</time_frame>
    <description>proportions of patients choosing an oral anticoagulation vs. patients choosing an injectable pathway depending on the duration of treatment (3 months, 6 months or more),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compare patients choosing oral anticoagulation vs patients choosing an injectable route</measure>
    <time_frame>the time required for a consultation: 30 minutes</time_frame>
    <description>Identify factors influencing these choices, depending on the characteristics of the patient (history, age, gender, social environment, personal experience).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Venous Thrombosis or Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Patients with venous thromboembolic disease</arm_group_label>
    <description>Patients with deep vein thrombosis, superficial or muscular vein thrombosis, pulmonary embolism, over 18 years of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>anticoagulation choice</intervention_name>
    <description>Type of anticoagulant chosen by the patient (oral or injectable).</description>
    <arm_group_label>Patients with venous thromboembolic disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with deep vein thrombosis, superficial vein thrombosis, muscle vein thrombosis or
        pulmonary embolism, over 18 years of age in France (via the vascular doctors of the French
        Society of Vascular MÃ©dicine).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with deep vein thrombosis, superficial vein thrombosis, muscle vein
             thrombosis or pulmonary embolism, over 18 years of age.

        No Exclusion Criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume Mahe</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cecile Ferragu</last_name>
    <phone>02 99 28 25 55</phone>
    <email>cecile.ferragu@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>direction de la recherche clinique</last_name>
    <phone>02 99 28 25 55</phone>
    <email>drc@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Mahe</last_name>
      <email>guillaume.mahe@chu-rennes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2019</study_first_posted>
  <last_update_submitted>March 21, 2019</last_update_submitted>
  <last_update_submitted_qc>March 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deep Vein Thrombosis</keyword>
  <keyword>Superficial Vein Thrombosis</keyword>
  <keyword>Anticoagulant</keyword>
  <keyword>Patient Compliance</keyword>
  <keyword>Preference</keyword>
  <keyword>Venous Thrombosis</keyword>
  <keyword>pulmonary embolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

